Here we present an X-ray crystallography structure of the clinically relevant tigecycline antibiotic bound to the 70S ribosome. Our structural and biochemical analysis indicate that the enhanced potency of tigecycline results from a stacking interaction with nucleobase C1054 within the decoding site of the ribosome. Singlemolecule fluorescence resonance energy transfer studies reveal that, during decoding, tigecycline inhibits the initial codon recognition step of tRNA accommodation and prevents rescue by the tetracycline-resistance protein TetM.
T etracyclines are broad-spectrum antibiotic agents that bind to elongating ribosomes and inhibit delivery of the ternary complex elongation factor thermo unstable (EF-Tu)·GTP·ami-noacyl (aa)-tRNA to the ribosomal A site (1) . Crystal structures of tetracyclines bound to the 30S subunit identified one common primary binding site that overlaps with the anticodon stem-loop of an A-site-bound tRNA (2) (3) (4) . The widespread use of tetracyclines in the past has led to an increase in acquired tetracyclineresistance determinants among clinically relevant pathogenic bacteria, limiting the utility of many members of this class. Of the variety of tetracycline-specific resistance mechanisms, efflux and ribosome protection are the most common (5) . Ribosome protection is mediated by ribosome protection proteins, with the best characterized being TetO and TetM (6) . Ribosome protection proteins bind to tetracycline-stalled translating ribosomes and chase the drug from the ribosome, thus allowing translation to continue. The third generation of tetracycline derivatives, such as tigecycline, display enhanced antimicrobial activity compared with tetracycline, as well as overcoming efflux and ribosome protection mechanisms (7, 8) .
Results and Discussion X-Ray Crystallography Structure of 70S·Tigecycline Complex. To address the molecular basis for the enhanced properties of tigecycline, we have determined an X-ray crystallography structure of tigecycline bound to a Thermus thermophilus 70S ribosome initiation complex containing P-site tRNA fMet and mRNA at 3.3-Å resolution ( Fig. 1A and Table S1 ). The binding site of tigecycline comprises nucleotides of helix 31 (h31) and helix 34 (h34) of the 16S rRNA located on the head of 30S subunit (Fig. 1B) . Electron density for tigecycline was observed only at the primary tetracycline binding site (Fig. S1 ) and not at any of the previously reported secondary tetracycline binding sites (2, 3) (Fig. S2 ), even though cocrystallization was performed at similar concentrations (60 μM) of tigecycline as used previously for tetracycline (4-80 μM) (2, 3) .
At 3.3-Å resolution, the tigecycline molecule could be unambiguously fit into the electron density ( Fig. 1C and Fig. S1 ), allowing the mode of interaction with the nucleotides of the 16S rRNA to be ascertained (Fig. 1D) . The polar edge of the tigecycline molecule, containing many hydrophilic functional groups, interacts directly with the phosphate-oxygen backbone of nucleotides C1195 and U1196 in h34 as well as indirectly with G1197-G1198 and C1054 via a coordinated Mg 2+ ion ( Fig. 1 D and E), as reported previously for tetracycline (2) . In addition, ring A of tigecycline coordinates a second Mg 2+ ion to facilitate an indirect interaction with the phosphate-backbone of G966 in h31 ( Fig. 1 C-E) . We also determined a structure of tetracycline bound to the T. thermophilus 70S ribosome initiation complex containing P-site tRNA fMet and mRNA at 3.45-Å resolution (Table S1 ). Interestingly, initial cocrystallization for tetracycline was performed by using the same conditions as for tigecycline, i.e., with 60 μM drug and fivefold excess of tRNA fMet vs. ribosomes; however, density for nonspecific binding of tRNA fMet in the A site was observed, rather than tetracycline (Fig. S3) . To obtain electron density for tetracycline, it was necessary to perform cocrystallization with higher concentrations of tetracycline (300 μM), coupled with lower excess (1.5-fold) of tRNA fMet vs. ribosomes (Fig. S4 ). These observations reemphasize the increased affinity of tigecycline vs. tetracycline for the ribosome (7-9), as well as illustrating the increased ability of tigecycline vs. tetracycline to compete with tRNA for binding at the A site. The structure of tetracycline bound to the 70S ribosome also suggests that tetracycline likely coordinates a second Mg 2+ ion ( Fig. 1E and Fig. S5 ), which was not suggested previously (2) . Moreover, we note that no density was observed for the loweraffinity secondary tetracycline binding sites under our crystallization conditions (2, 3) ( Fig. 1E and Fig. S6 ).
The major difference between tigecycline and tetracycline is the presence of 7-dimethylamido and 9-t-butylglycylamido moieties attached to ring D of tigecycline (Fig. 1D) . Whereas the 7-dimethylamido substitution does not establish interactions with the ribosome, the glycyl nitrogen atom of the 9-t-butylglycylamido moiety of tigecycline forms stacking interactions with the π-orbital of nucleobase C1054 of the 16S rRNA ( Fig. 1 C-E) . Strong electron density for the remainder of the 9-t-butylglycylamido moiety of tigecycline suggests that, despite the lack of any apparent contact with the ribosome, it adopts a very rigid conformation (Fig. 1C) , which may contribute to the stacking interaction with C1054. Indeed, binding of tigecycline appears to also enhance stacking between C1054 and U1196 ( Fig. 1 C and D) , similar to what is seen when tRNA is bound to the A site (10) (11) (12) . In contrast, these nucleotides appear more flexible and adopt diverse conformations in ribosome structures with an empty A site (Fig. S7) . The exclusive use of stacking and backbone interactions, together with the high structural conservation of the tetracycline binding site from bacteria to eukaryotes (13) (Fig.  1F ), is consistent with the broad-spectrum activity of tetracyclines (5) . Thus, we believe insights gained from the structures of tetracycline/tigecycline on the T. thermophilus ribosome can therefore be transferred to other bacteria. Although tetracycline activity has not been demonstrated against T. thermophilus strains to our knowledge, tetracyclines have been documented to have inhibitory activity against eukaryotic translation in vitro (14) (Fig. S8 ).
Binding and Inhibitory Properties of Tetracycline Derivatives. To investigate the contribution of the stacking interaction between the 9-t-butylglycylamido moiety of tigecycline and C1054, we used a series of tetracycline derivatives ( Fig. 2A ) and compared their ribosome binding (Fig. 2B ) and translation inhibitory properties (Fig. 2C) . The first two compounds tested, omadacycline (15) and 9-propylpyrrolidyl-7-fluorocyline (16) , have amide bond replacements in the 9-position ( Fig. 2A) . Based on the tigecycline·70S structure presented here, these compounds would not be expected to form efficient stacking interactions with C1054 ( Fig. 2 D and E) . Indeed, omadacycline and 9-propylpyrrolidyl-7-fluorocycline had significantly reduced binding affinities (IC 50 of 2 μM and 4 μM, respectively) with respect to tigecycline (IC 50 of 0.2 μM), and were comparable to tetracycline (IC 50 of 4 μM). Similar trends were also observed for the inhibition of an Escherichia coli in vitro translation system (Fig. 2C) , suggesting a strong correlation between binding affinity and translation inhibitory activity. Next, we rationalized that, if stacking with C1054 is important for drug activity, introduction of an additional aromatic ring to generate a pentacycline should allow π-orbital stacking (Fig. 2F) and thus improve the binding and inhibitory properties of the drug. Indeed, the 7-methoxy-10-azetidinomethyl pentacycline (17) exhibited improved binding affinity (IC 50 of 1 μM) and translation inhibitory activities (IC 50 of 1 μM) compared with tetracycline, although it was less potent than tigecycline ( Fig. 2 B and C) . Collectively, these data support the hypothesis that stacking interactions with C1054 enhance the binding and inhibitory properties of tetracycline derivatives.
Next we investigated the correlation between binding affinity and the ability to overcome TetM-mediated resistance. Here, we included 7-dimethylamido 8-azatetracycline (18) , which lacks a C9 substitution (Fig. 2 A and G ), yet had a similar binding affinity and translation inhibitory activity (both IC 50 s of 0.8 μM) as the 7-methoxy-10-azetidinomethyl pentacycline (IC 50 of 1 μM; Fig. 2 B and C) . To monitor the ability of each compound to Note that the nucleotide equivalents to C1054 and U1196 in S. cerevisiae are C1274 and A1427, the latter of which is slightly shifted, whereas the rest of the binding pocket is nearly identical.
overcome TetM-mediated resistance, the inhibitory effects of each compound were tested in an E. coli in vitro translation assay in the presence and absence of TetM (Fig. 2H) . As expected (8) , TetM dramatically relieved the translation inhibition of tetracycline, whereas TetM had no effect on the IC 50 of tigecycline (Fig. 2H) . Omadacycline, 9-propylpyrrolidyl-7-fluorocyline, and the 7-methoxy-10-azetidinomethyl pentacycline were all able to overcome TetM-mediated resistance, whereas 7-dimethylamido 8-azatetracycline, despite its increased binding affinity (Fig. 2B) , was not able to overcome TetM-mediated resistance, with the IC 50 increasing by ∼100 fold in presence of TetM (Fig. 2H ). These findings suggest that binding affinity alone is not sufficient to overcome TetM-mediated resistance. Instead, TetM resistance appears to depend more on the presence of bulky substitutions at the 9-position. Indeed, superimposition of the tigecycline·70S X-ray structure determined here with a recent structure of TetM bound to the 70S ribosome (19) reveals that the drug and TetM sterically overlap near the domain IV loop of TetM and the 9-tbutylglycylamido moiety of tigecycline (Fig. 2I ).
Effect of Tetracyclines and Glycylcyclines on tRNA Selection. To investigate the interplay among tigecycline, ternary complex EFTu·GTP·aa-tRNA, and TetM on the ribosome, we used singlemolecule fluorescence resonance energy transfer (FRET) imaging methods (20) . Delivery of ternary complex containing Cy5-labeled Phe-tRNA Phe to 70S ribosomes bound with Cy3-labeled tRNA fMet at the P-site was monitored via FRET between the donor (Cy3) and acceptor (Cy5) fluorophores upon tRNA binding to the A site (Fig. 3A) . In the absence of drug, tRNAs rapidly accommodated, resulting in the accumulation of a high (0.55) FRET state, previously shown to correspond to a pretranslocation complex configuration where A-and P-site tRNAs are classically positioned (20) (Fig. 3B ).
In the presence of tetracycline (40 μM; 10× K d ), aminoacyl-tRNA accommodation was efficiently blocked (21) , resulting in repetitive ternary complex binding and release events from a low-(∼0.2) FRET configuration, as anticipated from a defect in the selection process subsequent to codon recognition but before GTP hydrolysis (20, 21) (Fig. 3C ). The same experiment performed in the presence of tetracycline and TetM alleviated inhibition, restoring the capacity of aminoacyl-tRNA to rapidly accommodate into the A site, as evidenced by emergence of the high-FRET (∼0.55) state upon ternary complex delivery (Fig. 3D ). When ternary complex delivery to the ribosome was monitored in the presence of tigecycline (2 μM; 10× K d ), aminoacyl-tRNA accommodation was again efficiently blocked at the low-FRET state. However, the duration of the transient binding events was relatively short-lived compared with those observed in the presence of tetracycline, consistent with an increased potency of tigecycline in its capacity to inhibit the initial selection process (20, 21) ( Fig. 3E and Fig. S9 ). Strikingly, the addition of TetM did not alleviate the inhibition of ternary complex binding by tigecycline ( Fig. 3F) , consistent with the ability of tigecycline to overcome TetM-mediated resistance (7, 8) (Fig. 2I ).
Conclusion
Our findings indicate that the increased potency of tigecycline compared with tetracycline results from the increased affinity of tigecycline for the ribosome (7-9) (Fig. 1B ) via stacking interactions of the 9-t-butylglycylamido moiety of tigecycline with C1054 of the 16S rRNA (Figs. 1 C-E and 2D). The presence of 9-t-butylglycylamido moiety of tigecycline, rather than the increased affinity compared with tetracycline, enables tigecycline to overcome TetM-mediated resistance (Fig. 2H ). This observation is consistent with direct overlap of the 9-t-butylglycylamido moiety and domain IV loop of TetM (Fig. 2I) . Moreover, we show that tigecycline is much more effective at blocking the initial selection process of tRNA entry into the A site ( Fig. 3 C and E), in agreement with the steric clash between the drug and the anticodon stem-loop of the A-site tRNA (Fig. 3G ).
Materials and Methods
Reagents. Tetracycline (EMD Biosciences) and tigecycline (Sigma) were purchased from commercial sources, whereas PTK0796, TP767, pentacycline (TP556D), and azacycline (TP120C) were provided by Tetraphase. [ 3 H]Tetracycline was purchased from Perkin-Elmer. Ribosomes from T. thermophilus cells were isolated as described previously (22, 23) . Purified native uncharged E. coli tRNA fMet used for crystallographic studies was supplied by Chemical Block. The 30-nt-long mRNA [5′-GGCAAGGAGGUAAAA AUG UAC (A) 6 -3′] was purchased from Dharmacon (Shine-Dalgarno sequence and initiation codon are underlined). Labeling and charging of tRNA fMet (s 4 U8) and tRNA Phe (acp 3 U47) was as previously described by (21, 24, 25) . tRNA fMet (s 4 U8) and tRNA Phe (acp 3 U47) were purchased from Sigma. Recombinant purified TetM protein was prepared as described previously (26) .
Complex Formation and Crystallization. The ribosomal complexes were formed in 10 mM Tris-acetate, pH 7.0, 40 mM KCl, 7.5 mM magnesium acetate, 0.5 mM DTT, by incubating 70S ribosomes (3 μM) with mRNA, tRNA fMet , and antibiotic (tetracycline or tigecycline) for 30 min at 37°C. Crystals were grown at 24°C by sitting-drop vapor diffusion based on the previously described procedure (23) . Detailed methods can be found in SI Materials and Methods.
Data Collection, Processing, and Structure Determination. Data on all complexes were collected at 100 K at the Swiss Light Source, PSI, using the Pilatus 6M detector. A very low dose mode was used and huge redundancy was collected (27) . The initial model (from ref. 12 , with tRNAs, mRNA, and metal ions removed) was correctly placed within each data set with Phenix (28) by rigid body refinement with each molecule defined as a rigid body. A detailed description is provided in SI Materials and Methods.
Single-Molecule Fluorescence Experiments. Single-molecule FRET data were acquired by using a prism-based total internal reflection microscope as previously described (25, 29) . Detailed materials and methods can be found in SI Materials and Methods.
Binding and Inhibitory Assays. Inhibitory activity of the tetracycline compounds was assessed in an E. coli-coupled in vitro transcription/translation assay (5 PRIME) by using GFP fluorescence as a readout, as described previously (30, 31) . Binding of all tetracycline compounds to 70S ribosomes was examined by using a competition assay as described previously (8) . Further details can be found in SI Materials and Methods. 6 -3′] was purchased from Dharmacon (Shine-Dalgarno sequence and initiation codon are underlined). Recombinant purified TetM protein was prepared as described previously (3).
Complex Formation and Crystallization. The ribosomal complexes were formed in 10 mM Tris-Acetate, pH 7.0, 40 mM KCl, 7.5 mM magnesium acetate, 0.5 mM DTT by incubating 70S ribosomes (3 μM) with mRNA, tRNA fMet , and antibiotic (tetracycline or tigecycline) for 30 min at 37°C. Crystals were grown at 24°C by sitting-drop vapor diffusion based on the previously described procedure (2) . At first, tigecycline and tetracycline in their respective complexes were used in 20-fold excesses (60 μM final) of the ribosome and tRNA fMet in fivefold excess. Structure analysis showed a single binding site for tigecycline in both ribosomes in the asymmetric unit. In contrast, analysis of the ribosome complexes cocrystallized with tetracycline (in 20-fold stoichiometric excess) showed no drug bound to the ribosome. This crystal form (P2 1 2 1 2 1 ) contains two ribosome molecules per asymmetric unit (termed molecule A and molecule B). As a result of crystal packing, some peripheral parts are slightly different between the two molecules, but the core part of the ribosome remains the same. Molecule A is almost always better defined in the electron density, and therefore most interpretations are based on this molecule. In a previous study (2), we observed that the "initiation" complex formed with T. thermophilus 70S ribosomes cocrystallized with mRNA and tRNA fMet in conditions similar to the one used in the present study, which contains tRNA fMet in P-and E-sites of both ribosomes in the asymmetric unit. However, the A site was occupied by noncognate tRNA fMet in molecule A, whereas molecule B had an empty A site. The negative result from the tetracycline data demonstrates that, at the concentration and stoichiometric ratio used (60 μM; 20:1), tetracycline has much lower binding affinity than tigecycline, which was able not only to bind to the unoccupied A-tRNA site in molecule B, but also to compete with noncognate initiator tRNA fMet (which was present in fivefold excess) for the binding to the A site in molecule A. To achieve full binding of tetracycline in molecules A and B, we had to lower the stoichiometric excess of tRNA fMet to 1.5 and increase the excess of tetracycline to 100 times (300 μM final) the ribosome concentration.
Data Collection, Processing, and Structure Determination. Data on all complexes were collected at 100 K at the Swiss Light Source, PSI, using the Pilatus 6M detector. A very low dose mode was used, and huge redundancy was collected (4). The initial model (from ref. 5 , with tRNAs, mRNA, and metal ions removed) was correctly placed within each data set with Phenix (6) by rigid body refinement with each molecule defined as a rigid body. This was followed by rigid body refinement of individual subunits. After positional and B-factor refinement, the tRNAs and mRNA and were built in these unbiased electron density maps. In a subsequent round, the difference F obs −F calc electron density maps were inspected for possible locations of antibiotics, which were then built into the density (Figs. S2 and S6 ). Electron density for tigecycline and tetracycline was only observed at a single binding site (corresponding to the previously determined primary tetracycline binding site) and not at any of the previously reported secondary tetracycline binding sites (7, 8) (Fig. S1) . Moreover, crystallization of the 70S complex was performed in the presence of higher concentrations (300 μM) of tetracycline than used previously (4-80 μM). After several cycles of manual rebuilding followed by positional and individual isotropic B-factor refinement, magnesium ions were added. Apart from the structural magnesium coordinated by the phosphate oxygen atoms of C1054, G1197, and G1198 from helix 34 of 16S rRNA and the hydrophilic side of the tetracyclines, we found indications of a second magnesium involved in coordination of tetracycline antibiotics. This second putative magnesium is most strongly seen for the tigecycline complex (Fig. S1) , where it makes salt bridges with the phosphate oxygen atoms of G966 from helix 31 and the OH group at position 3 in ring A. In the tetracycline structure, the presence of this magnesium is much less obvious (Fig. S4) , possibly because of lower occupancy of the site or lower resolution of the data. However, when removing it from the tetracycline complex model, this magnesium repeatedly reappears in unbiased omit-averaged kick maps (9) . A summary of the crystallographic data and refinement statistics is given in Table S1 .
Aminoacylation and Fluorescent Labeling of tRNA for Single-Molecule
Fluorescence. tRNA fMet and tRNA Phe from E. coli strain MRE600 were obtained from commercial sources (Sigma). Aminoacylation, formylation, and fluorescent labeling of tRNA were performed as previously described (10) . By using this approach, Cy3 and Cy5 dyes (GE Healthcare) were site-specifically attached through maleimide or N-hydroxysuccinimide chemistry to tRNA Phe was achieved by using recombinant phenylalanyl tRNA synthetase prepared as previously described (10) (11) (12) . Dyelabeled tRNAs prepared in this manner are fully competent in tRNA selection, translocation, and peptide bond formation (10).
Preparation of Ribosome Complexes for Single-Molecule Fluorescence.
The 30S and 50S ribosomal subunits were isolated from E. coli strain BL21(DE3) as previously described (12) . Initiation complexes were prepared by using purified 50S and 30S subunits (1 μM each) initiated in vitro on 5′-biotinylated gene 32-derived mRNA (5′-biotin-CAA CCU AAA ACU UAC ACA CCC UUA GAG GGA CAA UCG AUG UUC AAA GUC UUC AAA GUC AUC; Dharmacon) in the presence of IF-1 (2 μM), IF-2 (2 μM), IF-3 (2 μM), 2 mM GTP, and fMet-tRNA fMet (Cy3-s 4 U8) in Tris-polymix buffer (pH 7.5) containing 50 mM Tris acetate, pH 7.5, 5 mM Mg(OAc) 2 , 100 mM KCl, 5 mM NH 4 OAc, 0.5 mM CaCl 2 , 0.1 mM EDTA, 5 mM putrescine, and 1 mM spermidine as previously described (10).
Single-Molecule Fluorescence Experiments and Data Processing. All experiments were performed in Tris-polymix buffer (pH 7.5) containing 50 mM Tris acetate, pH 7.5, 15 mM MgOAc, 100 mM KCl, 5 mM NH 4 OAc, 0.5 mM CaCl 2 , 0.1 mM EDTA, 5 mM putrescine, 1 mM spermidine, 5 mM β-mercaptoethanol, and 100 μM GTP, in the presence of an oxygen scavenging environment (2 mM protocatechuic acid and 50 nM protocatechuate-3,4-dioxygenase) containing a mixture of triplet-state quenching compounds (1 mM Trolox, 1 mM cyclooctatetraene, 1 mM nitrobenzyl alcohol) (13) . Ternary complex of elongation factor thermo unstable·GTP·Phe-tRNA Phe (Cy5-acp 3 U47) was prepared following established procedures (10, 12) . Ribosome complexes (0.5 nM) programmed with biotinylated mRNA were surface-immobilized following brief incubation within PEGpassivated, streptavidin-coated quartz microfluidic devices (12) . To avoid contributions of hybrid states formation following accommodation, the amino acid on P-site tRNA was released by incubating immobilized ribosomes with 2 mM puromycin (Sigma), pH 8.5, for 10 min.
Single-molecule fluorescence resonance energy transfer (FRET) data were acquired by using a prism-based total internal reflection microscope as previously described (12) . The Cy3 fluorophore linked to tRNA fMet was excited by the evanescent wave generated by total internal reflection of a single-frequency light source (532 nM; Ventus; Laser Quanta). Photons emitted from Cy3 and Cy5 were collected by using a 1.2 NA, 60× water-immersion objective (Nikon), with optical treatments used to spatially separate Cy3 and Cy5 frequencies onto a cooled, back-thinned electron-multiplying CCD camera (Evolve 512; Photometrics). Fluorescence data were acquired by using MetaMorph acquisition software (Universal Imaging) with an integration time of 200 ms. FRET trajectories were calculated from fluorescence trajectories by using the following formula: FRET = I Cy5 / (I Cy3 + I Cy5 ), where I Cy3 and I Cy5 represent the Cy3 and Cy5 fluorescence intensities, respectively. In each experiment, ternary complex solution was rapidly exchanged after ∼5 s of imaging.
Fluorescence and FRET traces were selected for analysis by using semiautomated single-molecule FRET analysis software implemented in Matlab (MathWorks) with use of the following criteria: a single catastrophic photobleaching event, total (donor plus acceptor) fluorescence intensity within 2 SDs of the mean, at least 8:1 signal-to-background noise ratio, fewer than four donor fluorophore blinking events, and a donor lifetime of at least 500 frames (100 s). FRET trajectories were idealized by using the segmental k-means algorithm (14) and a three-state, linear starting model with E FRET fixed as follows: 0.01 ± 0.061, 0.25 ± 0.08, and 0.56 ± 0.15. Each ribosome was assumed to have accommodated when a continuous dwell in the high FRET state was observed for at least 1 s (five frames).
E. coli-Coupled in Vitro Transcription/Translation Assay. Inhibitory activity of the tetracycline compounds was assessed in an E. colicoupled in vitro transcription/translation assay (5 PRIME) using GFP fluorescence as a read-out, as described previously (15, 16) . Serial dilutions spanning the activity range of each compound, 0.01 to 100 μM were performed, with the addition of 0.5 μM recombinant TetM protein when required. Reaction mixtures were performed in a total volume of 5 μL for 3 h at 30°C and stopped by placing on ice for 5 min. Subsequently, each reaction was diluted with 50 μL of buffer A (10 mM Hepes/KOH, pH 7.8, 10 mM MgCl 2 , 60 mM NH 4 Cl, 4 mM β-mercaptoethanol), mixed, and then transferred into black 96-well chimney plates (Greiner). The GFP fluorescence was measured on a Tecan Infinite M1000 reader with an excitation wavelength of 395 nm and emission of 509 nm. The results were represented graphically by using SigmaPlot (Systat). Binding of all tetracycline compounds to 70S ribosomes was examined by using a competition assay as described previously (17) . Briefly, all reaction mixtures contained 0.4 μM E. coli 70S ribosomes and 8 μM [ 4 Cl, 6 mM β-mercaptoethanol), which equated to 80% binding from the saturation curve. To measure the IC 50 for each of the compounds, reactions were performed in the absence or presence of increasing concentrations of the competing compounds. All compounds were tested at concentrations ranging from 0.01 to 10 μM, whereas tetracycline was tested at concentrations ranging from 0.01 to 75 μM. After incubation at room temperature for 2 h, reactions were passed through nitrocellulose filters, type HA, with 0.45-μm pore size (Millipore). Filters were washed three times with binding buffer, and radioactivity was determined by using a scintillation counter in the presence of Filtersafe (Zinsser Analytic) scintillant. Results presented are averages from at least two independent experiments. Fig. S1 . F obs −F calc difference map for tigecycline. (A and B) Two different views of the original F obs −F calc electron density map calculated before tigecycline was added to the model, contoured at 3 sigma. This completely unbiased map unambiguously shows the position of the antibiotic as well as the secondary magnesium ion (coordinated by G966). The first magnesium, which is a magnesium ion important for the structural integrity of the region and is always there regardless of antibiotics and ligands, shows up in this map because it was removed from the model before map calculation. 2)] for tetracycline found in the previous studies based on isolated 30S subunit soaked with tetracycline shown with our F obs −F calc map contoured at 2 sigma. Clearly, in our study, no tigecycline is bound at this site. (E-H) The remaining four binding sites located in one of the previous studies (1) . [A total of six tetracycline sites was found with only one (the "primary") having full occupancy.] Again, our maps clearly show that there is no antibiotic bound at these sites. In many cases, these "extra sites" are located in grooves of RNA that are well known for binding various ions or in areas that are very flexible with poorly defined electron density. Taken together with the data resolution and quality, it is therefore plausible that electron density for ions or extra electron density arising from poorly modeled areas could have been misinterpreted as bound antibiotics. Fig. S3 . F obs −F calc difference map for calculated for data collected on crystals cocrystallized in 20 μM tetracycline. The original F obs −F calc electron density map contoured at 3 sigma and calculated before any ligands (antibiotics, tRNAs, mRNAs) were added to the model. The presence of electron density for A-tRNA, but not for tetracycline, demonstrates that tetracycline at these conditions is not capable of competing with tRNA fMet for binding to the A site. 2)] for tetracycline found in the previous studies based on isolated 30S subunit soaked with tetracycline shown with our F obs −F calc map contoured at 2 sigma. Clearly, in our study, no tetracycline is bound at this/these site(s). (E-H) The remaining four binding sites located in one of the previous studies (2) . [A total of six tetracycline sites was found with only one (the primary) having full occupancy.] Again, our maps clearly show that there is no antibiotic bound at these sites. In many cases, these extra sites are located in grooves of RNA that are well known for binding various ions or in areas that are very flexible with poorly defined electron density. Taken together with the data resolution and quality, it is therefore plausible that electron density for ions or extra electron density arising from poorly modeled areas could have been misinterpreted as bound antibiotics. IDs: 3I9D, 2WDK, 2Y0Y, 4F5K, 2Y18, 3TVF, 4G5T) and isolated 30S (PDB IDs: 1HNW, 2F4V) with an A-site ligand (antibiotics or tRNAs). In contrast to C and D, the nucleotides C1054 and U1196 tend to become ordered when A-site ligands bind. It should be noted that these nucleotides being pyrimidines are easy to misrefine, as most refinement programs do not take π-stacking into account but mostly try to avoid stereochemical clashes. . Only a small difference in the orientation of nucleotide C1054 is observed, which seems to slightly adjust its position according to the ligand bound, whereas the rest of the pocket is identical between the two complexes. (Note: The A-tRNA was removed for clarity.) (C and D) Comparison of the 70S complexes with tigecycline (tigecycline in green, 16S RNA in cyan) and tetracycline (tetracycline in yellow, 16S rRNA in pink). These antibiotics are coordinated in the same way, and there is no significant difference in the binding pocket. The substitution at the 9-position of tigecycline enhances the stacking effect with C1054, but the orientation of these "stacking" nucleotides (C1054 and U1196) is the same for both antibiotic agents. (E and F) Comparison of the T. thermophilus 70S ribosome complex with tigecycline (tigecycline in green, 16S RNA in cyan) and the eukaryotic Saccharomyces cerevisiae 80S ribosome (18S rRNA in green/gold; PDB ID: 3U5B). In S. cerevisiae, an adenine is at the position corresponding to U1196; however, most of the tetracycline binding pocket is highly conserved, and, from the superposition, we see that this conservation is also true structurally. Slight shifts in helix 31 (h31) and helix 34 (h34) may be a result of the rotated state of the eukaryotic 80S ribosome (1) . Three and two crystals, respectively, were used to collect the data. ML, maximum likelihood; PDB, Protein Data Bank. *Highest resolution shell is shown in parenthesis. † I/σI of 2.0 at 3.3 Å and 3.45 Å, respectively, for the two datasets. ‡ Source: Phenix (1). 
